J&J asks for Remicade arbitration
This article was originally published in The Tan Sheet
Executive SummaryJohnson & Johnson says the details of Merck's complicated reverse merger with Schering-Plough do not circumvent changing control of a J&J-Schering partnership for a blockbuster rheumatoid arthritis franchise. On May 27, J&J requested an American Arbitration Association ruling that the March 9 Merck-Schering merger agreement constitutes a change of control that would terminate J&J subsidiary Centocor Ortho Biotech's 1998 deal with Schering about rheumatoid arthritis drug Remicade (infliximab) and the investigational follow-up Simponi (golimumab). Market analysts predicted J&J is capable of making a competing bid for Schering's consumer health business, but the firm was more likely to seek control of the Remicade partnership in response to the $41.1 billion merger agreement (1"The Tan Sheet" March 16, 2009, p. 4). J&J, which currently has U.S. marketing rights to the anti-TNFs, seeks Schering's marketing rights outside the U.S., excluding Japan and some Asian markets
You may also be interested in...
Company forecasts 2020 sales as high as $700m after regulator grants broad label.
Last week, the European Commission revealed that three more notified bodies had been designated, but their listings had not been made official. Now we learn that one of the three is in the Netherlands as the first listing takes place.